Case Report

Reversible Cortical Blindness after Lung Transplantation

Authors: Mark T. Knower, MD, Scott D. Pethke, MD, Vincent G. Valentine, MD

Abstract

Cyclosporine (CYA) is a calcineurin inhibitor widely used in immunosuppressive regimens after organ transplantation. Several neurologic side effects are frequently associated with CYA use; however, reversible cortical blindness is a rare manifestation of CYA toxicity traditionally seen after liver and bone marrow transplantation. This report presents a case of reversible cortical blindness after lung transplantation, then details the risk factors and clinical course of 28 previously well-documented cases of CYA-induced cortical blindness after transplantation. Identification of known risk factors, clinical clues, and typical radiographic findings may aid in the diagnosis of CYA-induced cortical blindness, since reduction in CYA dose or cessation of CYA therapy usually permits resolution of the neurologic effects.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Macoviak JA, Oyer PE, Stinson EB, Jamieson SW, Baldwin JC, Shumway NE. Four-year experience with cyclosporine for heart and heart-lung transplantation. Transplant Proc 1985; 17( Suppl): 97–101.
2. Walker RW, Brochstein JA. Neurologic complications of immunosuppressive agents. Neurol Clin 1988; 6: 261–279.
3. Drachman BM, DeNofrio D, Acker MA, Galetta S, Loh E. Cortical blindness secondary to cyclosporine after orthotopic heart transplantation: A case report and review of the literature. J Heart Lung Transplant 1996; 15: 1158–1164.
4. Estel RM, Gupta N, Garvin PJ. Permanent blindness after cyclosporine neurotoxicity in a kidney-pancreas transplant recipient. Clin Neuropharmacol 1996; 19: 259–266.
5. Rubin AM, Kang H. Cerebral blindness and encephalopathy with cyclosporin A toxicity. Neurology 1987; 37: 1072–1076.
6. Vaughn BV, Ali II, Olivier KN, Lackner RP, Robertson KR, Messenheimer JA, et al. Seizures in lung transplant recipients. Epilepsia 1996; 37: 1175–1179.
7. Rubin AM. Transient cortical blindness and occipital seizures with cyclosporine toxicity. Transplantation 1989; 47: 572–573.
8. Apaydin C, Gur B, Yakupoglu G, Saka O. Ocular and visual side effects of systemic cyclosporine. Ann Ophthalmol 1992; 24: 465–469.
9. Ghalie R, Fitzsimmons WE, Bennett D, Kaizer H. Cortical blindness: A rare complication of cyclosporine therapy. Bone Marrow Transplant 1990; 6: 147–149.
10. Wilson SE, deGroen PC, Aksamit AJ, Wiesner RH, Garrity JA, Krom RAF. Cyclosporin A-induced reversible cortical blindness. J Clin Neuroophthalmol 1988; 8: 215–220.
11. Schowengerdt KO, Gajarski RJ, Denfield S. Progressive visual deterioration leading to blindness after pediatric heart transplantation. Tex Heart Inst J 1993; 20: 299–303.
12. Memon M, deMagalhaes-Silverman M, Bloom EJ, Lister J, Myers DJ, Pincus SM, et al. Reversible cyclosporine-induced cortical blindness in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1995; 15: 283–286.
13. Vogt DP, Lederman RJ, Carey WD, Broughan TA. Neurologic complications of liver transplantation. Transplantation 1988; 45: 1057–1061.
14. Lee YT, Lee SG, Kwon TW, Park KM, Kim SC, Min PC. Neurologic complications after orthotopic liver transplantation including central pontine myelinolysis. Transplant Proc 1996; 28: 1674–1675.
15. Sterzi R, Santilli I, Donato MF, Erminio F, Belli LS, Belli L, et al. Neurologic complications following orthotopic liver transplantation. Transplant Proc 1994; 26: 3679–3680.
16. Nussbaum ES, Maxwell RE, Bitterman PB, Hertz MI, Bula W, Latchaw RE. Cyclosporine A toxicity presenting with acute cerebellar edema and brainstem compression. J Neurosurg 1995; 82: 1068–1070.
17. DeGroen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RAF. Central nervous system toxicity after liver transplantation: The role of cyclosporine and cholesterol. N Engl J Med 1987; 317: 861–866.
18. Lorberboym M, Bronster DJ, Lidov M, Pandit N. Reversible cerebral perfusion abnormalities associated with cyclosporine therapy in orthotopic liver transplantation. J Nucl Med 1996; 37: 467–469.
19. Wasserstein PH, Honig LS. Parkinsonism during cyclosporine treatment. Bone Marrow Transplant 1996; 18: 649–650.
20. Goldstein LS, Haug MT III, Perl J II, Perl MK, Maurer JR, Arroliga AC, et al. Central nervous system complications after lung transplantation. J Heart Lung Transplant 1998; 17: 185–191.
21. Adams DH, Ponsford S, Gunson B, Boon A, Honigsberger L, Williams A, et al. Neurologic complications following liver transplantation. Lancet 1987; 1: 949–951.
22. Kahan BD, Flechner SM, Lorber MI, Jensen C, Golden D, Van Buren CT. Complications of cyclosporine therapy. World J Surg 1986; 10: 348–360.
23. Tollemar J, Ringden O, Ericzon BG, Tyden G. Cyclosporine A-associated central nervous system toxicity. N Engl J Med 1988; 318: 788–789.
24. Hoefnagels WAJ, Gerritsen EJA, Brouwer OF, Souverijn JHM. Cyclosporin encephalopathy associated with fat embolism induced by the drug's solvent. Lancet 1988; 2: 901(letter).
25. Noll RB, Kulkarni R. Complex visual hallucinations and cyclosporine. Arch Neurol 1984; 41: 329–330.
26. Scheinman SJ, Reinitz ER, Petro G, Schwartz RA, Szmalc FS. Cyclosporine central neurotoxicity following renal transplantation. Report of a case using magnetic resonance images. Transplantation 1990; 49: 215–216.
27. Lopez Messa JB, Gonzalez Gomez N, Alonso Alonso P, Arranz Saez R, Sanchez Garcia M, Montalvo M, et al. Convulsions and arterial hypertension in 3 patients who had undergone bone marrow transplant and treatment with cyclosporin A [in Spanish]. Rev Clin Esp 1986; 178: 186–188.
28. Reece DE, Frei-Lahr DA, Shepherd JD, Dorovini-Zis K, Gascoyne RD, Graeb DA, et al. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. Bone Marrow Transplant 1991; 8: 393–401.
29. Edwards LL, Wszolek ZK, Normand MM. Neurophysiologic evaluation of cyclosporine toxicity associated with bone marrow transplantation. Acta Neurol Scand 1996; 94: 358–364.
30. Uoshima N, Karasuno T, Yagi T, Kawamoto S, Hasegawa T, Yasumi M, et al. Late onset cyclosporine-induced cerebral blindness with abnormal SPECT imagings in a patient undergoing unrelated bone marrow transplantation. Bone Marrow Transplant 2000; 26: 105–108.
31. Madan B, Schey SA. Reversible cortical blindness and convulsions with cyclosporin A toxicity in a patient undergoing allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 1997; 20: 793–795.
32. Casanova B, Prieto M, Deya E. Persistent cortical blindness after cyclosporine leukoencephalopathy. Liver Transpl Surg 1997; 3: 638–640.
33. Jarosz JM, Howlett DC, Cox TCS, Bingham JB. Cyclosporine-related reversible posterior leukoencephalopathy: MRI. Neuroradiology 1997; 39: 711–715.
34. Antunes NL, Small TN, George D, Boulad F, Lis E. Posterior leukoencephalopathy syndrome may not be reversible. Pediatr Neurol 1999; 20: 241–243.
35. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 494–500.
36. Arnoldus EPJ, Van Laar T. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 1745(letter).
37. Wilczek H, Ringden O, Tyden G. Cyclosporine-associated central nervous system toxicity after renal transplantation. Transplantation 1985; 39: 110.
38. Schwartz RB, Bravo SM, Klufas RA, Hsu L, Barnes PD, Robson CD, et al. Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol 1995; 165: 627–631.
39. Pace MT, Slovis TL, Kelly JK, Abella SD. Cyclosporin A toxicity: MRI appearance of the brain. Pediatr Radiol 1995; 25: 180–183.
40. Shirai A, Naito M, Tatsuta T, Dong J, Hanaoka K, Mikami K, et al. Transport of cyclosporine A across the brain capillary endothelial cell monolayer by P-glycoprotein. Biochim Biophys Acta 1994; 1222: 400–404.
41. Kunzendorf U, Brockmoller J, Jochimsen F, Keller F, Walz G, Offermann G. Cyclosporine metabolites and central-nervous-system toxicity. Lancet 1988; 1: 1223(letter).
42. Wadhwa NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplantation 1987; 43: 211–213.
43. Cooper DKC, Novitzky D, Davis L, Huff JE, Parker D, Schlesinger R, et al. Does central nervous system toxicity occur in transplant patients with hypocholesterolemia receiving cyclosporine? J Heart Transplant 1989; 8: 221–224.
44. Gurecki J, Warty V, Sanghvi A. The transport of cyclosporine in association with plasma lipoproteins in heart and liver transplant patients. Transplant Proc 1985; 17: 1997–2002.
45. Nemunaitis J, Deeg HJ, Yee GC. High cyclosporine levels after bone marrow transplantation associated with hypertriglyceridemia. Lancet 1986; 2: 744–745(letter).
46. Joss DV, Barrett AJ, Kendra JR, Lucase CF, Desai S. Hypertension and convulsions in children receiving cyclosporine A. Lancet 1982; 1: 906(letter).
47. Siegel H, Ryffel B, Petric R. Cyclosporine, the renin-angiotensin-aldosterone system and renal adverse effects. Transplant Proc 1983; 15: 2719–2725.
48. Siegel H, Ryffel B. Effect of cyclosporin on renin-angiotensin-aldosterone system. Lancet 1982; 2: 1274(letter).
49. Truwit CL, Denaro CP, Lake JR, DeMarco T. MR imaging of reversible cyclosporin A-induced neurotoxicity. Am J Neuroradiol 1991; 12: 651–659.
50. Thompson CB, June CH, Sullivan KM, Thomas ED. Association between cyclosporin neurotoxicity and hypomagnesemia. Lancet 1984; 2: 1116–1120.
51. Racusen LC, McCrindle BW, Christenson M, Fivush B, Fisher RS. Cyclosporine lowers seizure threshold in an experimental model of electroshock-induced seizures in Munich-Wistar rats. Life Sci 1990; 46: 1021–1026.
52. Nordal KP, Talseth T, Dahl E, Attramadal A, Albrechtsen D, Halse J, et al. Aluminium overload, a predisposing condition for epileptic seizures in renal-transplant patients treated with cyclosporin? Lancet 1985; 2: 153–154(letter).
53. Durrant S, Chipping PM, Palmer S, Gordon-Smith EC. Cyclosporin A, methylprednisolone, and convulsions. Lancet 1982; 2: 829–830(letter).
54. Hwang WL, Gau JP, Young JH, Chia LG. Ketoconazole and high-dose methylprednisolone predisposing to cyclosporine-induced seizures: Report of three cases. Acta Haematol 1992; 88: 139–141.
55. Klintmalm G, Sawe J. High-dose methylprednisolone increases plasma cyclosporin levels in renal transplant recipients. Lancet 1984; 1: 731(letter).
56. Bechstein WO. Neurotoxicity of calcineurin inhibitors: Impact and clinical management. Transplant Int 2000; 13: 313–326.
57. Steg RE, Kessinger A, Wszolek ZK. Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation. Bone Marrow Transplant 1999; 23: 959–962.
58. Devine SM, Newman NJ, Siegel JL, Joseph GJ, Geis TC, Schneider JA, et al. Tacrolimus (FK506)-induced cerebral blindness following bone marrow transplantation. Bone Marrow Transplant 1996; 18: 569–572.
59. Small SL, Fukui MB, Bramblett GT, Eidelman BH. Immunosuppression-induced leukoencephalopathy from tacrolimus (FK506). Ann Neurol 1996; 40: 575–580.

The old law about “an eye for an eye” leaves everybody blind. - —Martin Luther King, Jr.